Assessment of utility of Remdesivir in Patients with Acute Kidney Injury or Cronic Kidney Disease in admitted COVID-19 patients

Phase 3

Recruiting

• Conditions: Coronavirus infection, unspecified; Condition 1: COVID-19. Condition 2: Acute Kidney Injury. Condition 3: Chronic Kidney Disease.; Acute kidney failure; Chronic kidney disease (CKD); B34.2

• Registration Number: IRCT20210709051824N1
• Lead Sponsor: Men's Health and Reproductive Health Research Center(MHRHRC)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Patients with acute or chronic renal failure, with a definitive diagnosis of Covid 19, over the age of 18 years, and lung involvement above 20% or hypoxia (oxygen saturation less than or equal to 93%)
Definitive diagnosis of Covid 19
Over the age of 18 years
Pulmonary involvement caused by Covid 19

Exclusion Criteria

Previous history of COVID-19 infection and heart disease and receiving Remdesivir
History of lung disease
History of liver disease (such as hepatitis, cirrhosis)
History of underlying diseases other than renal impairment that contribute to poor prognosis and increased mortality following coronary heart disease (eg, heart failure, active cancer, advanced diabetes with severe macrovascular and microvascular complications, previous stroke)
Immunosuppressive use except in the field of kidney transplantation
Prohibition of Ramdesivir (except low GFR)

Study & Design

• Study Type: interventional
• Study Design: Not specified